Market Research Logo

Global Dermatology Drugs Market to 2023 - Growth Driven by Increased Uptake of Interleukin Receptor Inhibitors for Psoriasis and Atopic Dermatitis

Global Dermatology Drugs Market to 2023 - Growth Driven by Increased Uptake of Interleukin Receptor Inhibitors for Psoriasis and Atopic Dermatitis

Summary


Dermatology is a highly diverse therapy area that deals with diseases of the skin, hair and nails. Over 3,000 types of dermatological conditions are thought to exist, ranging from the autoimmune disorder psoriasis to the very common condition acne vulgaris. The scope of dermatological disorders is diverse in terms of severity and clinical presentation, and if a condition is not sufficiently kept under control, it can significantly impair the patient’s quality of life. For example, patients with severe atopic dermatitis (the most common form of eczema) may experience mobility impairments and debilitating itching, which may interfere with daily activities. Furthermore, most dermatological conditions are visible, and as such can have a profound impact on patient confidence.

There are 850 products in the dermatology pipeline with a disclosed stage of development, but the majority of these drugs are at an early stage of development. Some 42% of the pipeline is in the Preclinical stage, while 14% is in the discovery stage. However, 32% of the pipeline is in clinical development, but only 3% are in the Pre-registration stage and less than half are novel.

Four drugs that were approved for psoriasis are Cosentyx, Otezla, Eucrisa and Taltz. The most notable of the four are Cosentyx and Otezla, which were approved in 2015 and 2014, respectively, and are forecast to generate $3.8 billion and $2.7 billion from the therapy area in 2023, respectively. The two most recently approved psoriasis treatments, Taltz and Eucrisa, are not expected to achieve the same level of commercial success as Cosentyx or Otezla because they are entering a market that is already saturated with entrenched competitors that have reduced the level of unmet need.

Dermatology therapy area is dominated by top 20 pharma companies. In 2016 the most commercially successful companies in the therapy area were Johnson & Johnson, AbbVie, Amgen, Novartis and Pfizer. Across the forecast period these companies will continue to generate high revenue, but the companies will all see their market shares change.

The report “Global Dermatology Drugs Market to 2023 - Growth Driven by Increased Uptake of Interleukin Receptor Inhibitors for Psoriasis and Atopic Dermatitis” provides an introduction to dermatology, including disease epidemiology, symptoms, etiology, pathophysiology, co-morbidities and complications. Disease classification and methods of diagnosis are also provided.

In depth, this report provides the following -

  • Provides an overview of the dermatology marketed products landscape, including product profiles of key marketed products and revenue projections for each of these drugs.
  • Analyzes the dermatology pipeline, detailing, among other parameters, drug distribution by stage of development, molecule type and molecular target, plus an analysis of the key indications in the pipeline: atopic dermatitis, acne vulgaris and psoriasis.
  • Presents forecast projections to 2022 on a global level, with forecasts provided for the US, plus aggregate revenue forecasts of the top five EU markets (the UK, France, Germany, Italy and Spain) and Japan. Additionally, revenue forecasts for the major product categories and key players are provided.
  • Assesses the company landscape in dermatology, with an analysis of the key players, the types of company involved in this therapy area, and whether this therapy area composes a large proportion of each company’s pipeline portfolio and total revenues.
Companies mentioned in this report: Johnson & Johnson, AbbVie, Amgen, Novartis, Pfizer

Scope
  • Global revenue from the dermatology market is forecast to increase from $19.8 billion in 2016 to $36.6 billion in 2023, at a compound annual growth rate of 9.13%. Which drugs will achieve blockbuster status and how will the key player companies perform during the forecast period?
  • What are the leading companies in terms of market share?
  • Which companies are forecast to experience the largest growth in market share?
  • Which companies rely heavily on revenue derived from antibacterial drugs?
  • How will the market respond to recent approvals?
  • Will generics and biosimilars have a significant impact on the market over the forecast period?
  • What class of drugs dominate the market?
  • What molecular targets are most popular in the pipeline?
  • What are the commercial prospects for the most promising late-stage products?
Reasons to buy
  • Understand the current treatment landscape, with portfolios of key marketed products and a focus on historical and forecast sales patterns, and an overview of each drug’s mechanism of action.
  • Analyze the dermatology pipeline through a comprehensive review of the pipeline segmented by stage of development, molecule type and molecular target.
  • This review also provides a detailed look at dermatology product clinical trials to provide an insight into the risk associated with attempting to bring pipeline products to market.
  • Predict growth in market size, with in-depth market forecasting from 2016 to 2023. The forecasts will provide an understanding of how epidemiology trends, new drug entries, and patent expirations will influence market value.
  • Identify commercial opportunities in the dermatology deals landscape by analyzing trends in licensing and co-development deals.


  • GBI Research Report Guidance
  • Executive Summary
  • Introduction
    • Therapy Area Introduction
    • Symptoms
    • Etiology and Pathophysiology
      • Atopic Dermatitis
      • Acne Vulgaris
      • Psoriasis
    • Co-morbidities and Complications
    • Diagnosis, Scales and Grading
      • Atopic Dermatitis
        • Table Dermatology, Global, Classification of Atopic Dermatitis Severity and Impact on Quality of Life
      • Acne Vulgaris
        • Table Dermatology, Global, European Dermatology Forum Acne Vulgaris Classification
        • Table Dermatology, Global, Classification of Acne Vulgaris Severity
      • Psoriasis
        • Table Dermatology, Global, Classification of Psoriasis Severity
    • Epidemiology Patterns and Forecasts – Prevalence and Patient Segmentation
      • Table Dermatology, Global, Epidemiology of Dermatological Disorders, 2016
      • Atopic Dermatitis
        • Table Figure 1: Epidemiology Patterns for Atopic Dermatitis (million), 2016–
      • Acne Vulgaris
        • Table Figure 2: Epidemiology Patterns for Acne Vulgaris (million), 2016–
      • Psoriasis
        • Table Figure 3: Epidemiology Patterns for Psoriasis (million), 2016–
    • Treatment
      • Topical Corticosteroids
      • Calcineurin Inhibitors
      • Retinoids
      • Systemic Immunosuppressive Agents
      • Biologics
      • Antihistamines
      • Hormonal Therapy
      • Moisturizers
  • Key Marketed Products
    • Overview
      • Table Figure 4: Dermatology, Global, Key Marketed Products and Approved Indications, 2017
    • Humira (adalimumab) – AbbVie
      • Table Dermatology Therapeutics Market, Global, Approved Dermatology Indications for Humira, 2017
      • Table Figure 5: Dermatology Therapeutics Market, Global, Annual Revenue for Humira ($bn), 2006–2023
    • Remicade (infliximab) – Johnson & Johnson
      • Table Dermatology Therapeutics Market, Global, Approved Dermatology Indications for Remicade, 2017
      • Table Figure 6: Dermatology Therapeutics Market, Global, Johnson & Johnson's Annual Revenue for Remicade ($bn), 2006–2023
      • Table Figure 7: Dermatology Therapeutics Market, Global, Merck & Co.' s Annual Revenue for Remicade ($bn), 2010–2023
    • Enbrel (etanercept) – Amgen
      • Table Dermatology Therapeutics Market, Global, Approved Dermatology Indications for Enbrel, 2017
      • Table Figure 8: Dermatology Therapeutics Market, Global, Amgen's Annual Revenue for Enbrel ($bn), 2006–2023
      • Table Figure 9: Dermatology Therapeutics Market, Global, Pfizer's Annual Revenue for Enbrel ($bn), 2010–2023
    • Stelara (ustekinumab) – Johnson & Johnson
      • Table Dermatology Therapeutics Market, Global, Approved Dermatology Indications for Stelara, 2017
      • Table Figure 10: Dermatology Therapeutics Market, Global, Annual Revenue for Stelara ($bn), 2010–2023
    • Neoral (cyclosporine) – Novartis
      • Table Dermatology Therapeutics Market, Global, Approved Dermatology Indications for Neoral, 2017
      • Table Figure 11: Dermatology Therapeutics Market, Global, Annual Revenue for Neoral ($m), 2006–2023
    • Protopic (tacrolimus) – Astellas Pharma
      • Table Dermatology Therapeutics Market, Global, Approved Dermatology Indications for Protopic, 2017
      • Table Figure 12: Dermatology Therapeutics Market, Global, Annual Revenue for Protopic ($m), 2006–2015
    • Cosentyx (Secukinumab) – Novartis
      • Table Dermatology Therapeutics Market, Global, Approved Dermatology Indications for Cosentyx, 2017
      • Table Figure 13: Dermatology Therapeutics Market, Global, Revenue Forecast for Cosentyx ($bn), 2016–2023
    • Dupixent (dupilumab) Sanofi and Regeneron
      • Table Dermatology Therapeutics Market, Global, Approved Dermatology Indications for Dupixent, 2017
      • Table Figure 14: Dermatology Therapeutics Market, Global, Revenue Forecast for Dupilumab ($bn), 2017–2023
      • Table Figure 15: Dermatology Therapeutics Market, Global, Revenue Forecast for Taltz ($bn), 2017–2023
    • Taltz (ixekizumab) – Eli Lilly
      • Table Dermatology Therapeutics Market, Global, Approved Dermatology Indications for Taltz, 2017
      • Table Figure 16: Dermatology Therapeutics Market, Global, Revenue Forecast for Taltz ($bn), 2016–2023
    • Eucrisa (crisaborole) - Pfizer
      • Table Dermatology Therapeutics Market, Global, Approved Dermatology Indications for Eucrisa, 2017
      • Table Figure 17: Dermatology Therapeutics Market, Global, Revenue Forecast for Eucrisa ($bn), 2016–2023
    • Siliq (Brodalumab) – Valeant Pharmaceuticals
      • Table Dermatology Therapeutics Market, Global, Approved Dermatology Indications for Siliq, 2017
      • Table Figure 18: Dermatology Therapeutics Market, Global, Revenue Forecast for AMG-827 ($m), 2016–2022
    • Elidel (pimecrolimus)
      • Table Dermatology Therapeutics Market, Global, Approved Dermatology Indications for Elidel, 2015
    • Elocon (mometasone furoate)
      • Table Dermatology Therapeutics Market, Global, Approved Dermatology Indications for Elocon, 2015
    • Differin (adapalene)
      • Table Dermatology Therapeutics Market, Global, Approved Dermatology Indications for Differin, 2015
    • Metolate (methotrexate)
      • Table Dermatology Therapeutics Market, Global, Approved Dermatology Indications for Metolate, 2017
    • Clobex (clobetasol propionate)
      • Table Dermatology Therapeutics Market, Global, Approved Dermatology Indications for Clobex, 2017
    • Conclusion
  • Pipeline Landscape Assessment
    • Overview
      • Table Figure 19: Dermatology Therapeutics Market, Global, Overall Pharmaceutical Industry Pipeline by Therapy Area, 2017
      • Table Figure 20: Dermatology Therapeutics Market, Global, Pipeline for Dermatology by Stage of Development, Molecule Type and Program Type, 2017
      • Table Figure 21: Dermatology Therapeutics Market, Global, Pipeline for Key Dermatology Indications by Stage of Development, 2017
    • Molecule Types in the Pipeline
      • Table Figure 22: Dermatology Therapeutics Market, Global, Pipeline for Key Dermatology Indications by Molecule Type, 2017
    • Molecular Targets in the Pipeline
      • Table Figure 23: Dermatology Therapeutics Market, Global, Pipeline for Dermatology by Molecular Target and stage of development, 2017
      • Table Figure 24: Dermatology Therapeutics Market, Global, Pipeline for Dermatology by Molecular Target, 2017
      • Table Figure 25: Dermatology Therapeutics Market, Global, Pipeline for Key Dermatology Indications by Molecular Target, 2017
    • Clinical Trials
      • Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target
        • Table Figure 26: Dermatology Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development (%), 2006–2017
        • Table Figure 27: Dermatology Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Indication (%), 2006–2016
        • Table Figure 28: Dermatology Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecule Type (%), 2006–2016
        • Table Figure 29: Dermatology Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecular Target (%), 2006–2016
      • Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target
        • Table Figure 30: Dermatology Therapeutics Market, Global, Clinical Trial Duration by Stage of Development (months), 2006–2017
        • Table Figure 31: Dermatology Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Indication (months), 2006–2017
        • Table Figure 32: Dermatology Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecule Type (months), 2006–2016
        • Table Figure 33: Dermatology Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecular Target (months), 2006–2016
      • Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target
        • Table Figure 34: Dermatology Therapeutics Market, Global, Clinical Trial Size by Stage of Development (patients), 2006–2016
        • Table Figure 35: Dermatology Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Indication (participants), 2006–2016
        • Table Figure 36: Dermatology Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Molecule Type (participants), 2006–2016
        • Table Figure 37: Dermatology Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Molecular Target (participants), 2006–2016
      • Aggregate Clinical Program Size by Stage of Development, Indication, Molecule Type and Molecular Target
        • Table Figure 38: Dermatology Therapeutics Market, Global, Clinical Program Size by Stage of Development (months), 2006–2016
        • Table Figure 39: Dermatology Therapeutics Market, Global, Clinical Program Size by Stage of Development and Indication (participants), 2006–2016
        • Table Figure 40: Dermatology Therapeutics Market, Global, Clinical Program Size by Stage of Development and Molecule Type (participants), 2006–2016
        • Table Figure 41: Dermatology Therapeutics Market, Global, Clinical Program Size by Stage of Development and Molecular Target (participants), 2006–2017
      • Assessment of Key Pipeline Products
        • Table Figure 42: Dermatology Therapeutics Market, Global, Revenue Forecast for Risankizumab ($m), 2016–2022
        • Table Figure 43: Dermatology Therapeutics Market, Global, Revenue Forecast for Zorblisa ($m), 2017–2023
        • Table Figure 44: Dermatology Therapeutics Market, Global, Revenue Forecast for Olumacostat glasaretil ($m), 2019–2023
        • Table Figure 45: Dermatology Therapeutics Market, Global, Revenue Forecast for Guselkumab ($m), 2016–2022
    • Conclusion
  • Multi-scenario Market Forecast to 2023
    • Overall Market Size
      • Table Figure 46: Dermatology Global, Market Size ($bn), 2016–2023
      • Table Dermatology Therapeutics Market, Global, Annual Revenue Forecast for Key Products ($bn), 2016–2023
    • Generic Penetration
      • Table Figure 47: Dermatology Global, Annual Revenue Forecast for Key Products ($bn), 2016–2023
      • Table Dermatology, Global, Usage of Generics Across Key Indications, 2017
    • Revenue Forecast by Molecular Target
      • Tumor Necrosis Factor-Alpha
        • Table Figure 48: Dermatology, Global, Annual Revenue Forecast for Tumor Necrosis Factor-Alpha Inhibitors ($bn), 2016–2023
      • Interleukins 1, 4, 5, 12, 17 and 23 and Receptors
        • Table Figure 49: Dermatology, Global, Annual Revenue Forecast for Interleukin Inhibitors ($bn), 2015–2022
      • Calcineurin
        • Table Figure 50: Dermatology, Global, Annual Revenue Forecast for Calcineurin Inhibitors ($bn), 2015–2022
      • Glucocorticoid Receptors
        • Table Figure 51: Dermatology, Global, Annual Revenue Forecast for Glucocorticosteroids ($m), 2015–2022
      • Phosphodiesterase 4
        • Table Figure 52: Dermatology, Global, Annual Revenue Forecast for Phosphodiesterase 4 inhibitors ($bn), 2015–2023
  • Company Analysis and Positioning
    • Table Figure 53: Dermatology Therapeutics Market, Global, Cluster by Growth and Market Share, 2016-2023
    • Revenue and Market Share Analysis by Company
      • Table Dermatology Therapeutics Market, Global, Forecast Revenue by Company, 2016–2023
      • Table Figure 54: Dermatology Therapeutics Market, Global, Forecast Market Share by Company (%), 2016–2023
      • Table Figure 55: Dermatology, Global, Companies by Compound Annual Growth Rate (%), 2016–2023
      • Table Figure 56: Dermatology, Global, Revenues by Product Type, 2016–2023
      • Novartis – Will Revenue from Cosentyx Continue to Increase in the Forecast Period?
        • Table Figure 57: Dermatology, Global, Novartis, Annual Revenue Forecast ($bn), 2016–2023
      • AbbVie – Will Humira's Patent Expiry Lead to Loss of Market Leadership?
        • Table Figure 58: Dermatology, Global, AbbVie Annual Revenue Forecast ($bn), 2016–2023
      • Johnson & Johnson – Guselkumab and Stelara Fail to Offset Revenue Lost from Remicade
        • Table Figure 59: Dermatology, Global, Johnson & Johnson Annual Revenue Forecast ($bn), 2015–2022
      • Sanofi – High Revenue Growth from Dupixent Will See Sanofi's Revenue from the Dermatology Therapy Area Increase
        • Table Figure 60: Dermatology, Global, Sanofi, Annual Revenue Forecast ($bn), 2015–2022
      • Pfizer – Approval of Eucrisa to Drive Growth in the Dermatology Therapy Area
        • Table Figure 61: Dermatology, Global, Pfizer Annual Revenue Forecast ($bn), 2015–2022
      • Celgene –
        • Table Figure 62: Dermatology, Global, Celgene Annual Revenue Forecast ($bn), 2016–2023
    • Company Landscape
      • Table Figure 63: Dermatology, Global, Companies by Type, 2017
    • Marketed and Pipeline Portfolio Analysis
      • Table Figure 64: Dermatology, Global, Pipeline, High-Activity and Late-Stage Developers by Level of Dermatology Specialization, 2017
      • Table Figure 65: Dermatology, Global, Proportion of Total Company Revenue Attributed to Dermatology, 2015–2022
  • Strategic Consolidations
    • Licensing Deals
      • Deals by Region, Year and Value
        • Table Figure 66: Dermatology, Global, Licensing Deals, 2006–2017
        • Table Figure 67: Dermatology, Global, Licensing Deals by Indication, 2006–2017
      • Deals by Stage of Development and Value
        • Table Figure 68: Dermatology, Global, Licensing Deals by phase and value, 2006–2017
      • Deals by Molecule Type, Mechanism of Action and Value
        • Table Figure 69: Dermatology, Global, Licensing Deals by Molecule Type and Mechanism of Action, 2006–2017
      • Figures for Licensing Deals Valued Above $100m
        • Table Figure 70: Dermatology Therapeutics Market, Global, Licensing Deals, 2006–2017
    • Co-development Deals
      • Deals by Region, Year and Value
        • Table Figure 74: Dermatology, Global, Co-development Deals, 2006–2017
        • Table Figure 75: Dermatology, Global, Co-development Deals by Indication, 2006–2017
      • Deals by Stage of Development and Value
        • Table Figure 76: Dermatology, Global, Co-development Deals by phase and value, 2006–2017
      • Deals by Molecule Type, Mechanism of Action and Value
        • Table Figure 77: Dermatology, Global, Co-development Deals by Molecule Type and Mechanism of Action, 2006–2017
      • Figures for Co-development Deals Valued Above $100m
        • Table Figure 78: Dermatology Therapeutics Market, Global, Co-development Deals, 2006–2017
  • Appendix
    • References
    • Table of Epidemiology Forecast
      • Table Epidemiology Patterns for Atopic Dermatitis, 2015–2022
      • Table Epidemiology Patterns for Acne Vulgaris, 2015–2022
      • Table Epidemiology Patterns for Psoriasis, 2015–2022
    • Figure of All Clinical Stage Psoriasis ,Atopic dermatitis and Acne vulgaris Pipeline Products
      • Table Figure 82: Dermatology, Global, Table of all Clinical Stage Pipeline Products, 2016
    • Abbreviations
      • Table Abbreviations
    • Disease List
    • Methodology
      • Coverage
      • Secondary Research
      • Market Size and Revenue Forecasts
      • Pipeline Analysis
      • Competitive Landscape
    • Contact Us
    • Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report